Bronchiectasis Pipeline, 2025

The global bronchiectasis pipeline and drug development landscape is steadily evolving as pharmaceutical companies and research organizations leverage efforts to develop drugs mostly for treating chronic airway inflammation and mucus clearance. The number of recurrent respiratory infections with complications has increased, thereby demanding newer therapies.

The pipeline covers several drug candidates at various points of development that seek to reduce exacerbations, improve lung function, and increase patients' quality of life.

Bronchiectasis Pipeline Insights 2025: Report Scope

The “Bronchiectasis - Pipeline Insight, 2025” report by Fortune Business Insights provides comprehensive insights covering 15+ companies and 15+ pipeline drugs. It looks at drugs by their phase of advancement, how they are given, the group they belong to, their makeup, and the target they address. Each company profile covers its introduction, action path, research progress, financial info, and indications for which it is used. The document looks at both old and no longer produced products, along with key statistics and an overview of the market. It shows how drug development and clinical research occur in the main geographic regions, shedding light on new therapies, clinical developments, mechanisms of action, regulatory updates, collaborations, and important product development paradigms.

Besides, it helps keep readers informed about the newest trends and main changes in the industry. The sections of the report look at North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Reasons to Buy this Report

• Understand the main factors behind Bronchiectasis leading to the development of new treatment methods.
• Know that the Bronchiectasis market is growing as there is now more awareness and higher healthcare spending globally.
• You can explore full profiles of leading pharmaceutical firms and the Bronchiectasis medicines they are researching in every stage of development.
• Find out about the main problems and challenges in Bronchiectasis research, such as unique therapies being looked into.
• Thoroughly analyze the pipeline to help guide strategy, refine your product portfolio, and discover possible partners or acquisition choices.

Know Answers to Your Questions:

• What is the number of companies developing Bronchiectasis drugs?
• How many Bronchiectasis drugs is each company developing?
• How many Bronchiectasis treatment drugs are in mid- and late-stage development?
• What are the recent collaborations, mergers and acquisitions, and licensing related to Bronchiectasis therapeutics?
• What are the emerging trends and drug types and what novel technologies are under development to overcome the limitations of current Bronchiectasis treatments?
• How many clinical trials are underway for Bronchiectasis drugs and in what phase are they?
• What are the major designations granted to emerging Bronchiectasis drug candidates?

Report Methodology

• All pipeline review reports are created by means of data analysis, mainly gathered through desk research from credible sources, which is then supplemented by key opinion leader interviews.
• Desk research sources include listings from global or regional clinical trial registries, annual reports from companies, official websites, press releases, investor presentations, white papers, news articles, reports from industry associations, and publications from databases such as NCBI and ResearchGate, among others, including internal databases.

Clinical Trial Insights:

An increasing demand for effective treatment options has driven the expansion of bronchiectasis drug pipeline R&D activity. Clinical trial results are being produced by numerous research institutions, healthcare organizations, and pharmaceutical companies to come up with therapeutic alternatives. Governments have also contributed to research measures related to bronchiectasis globally by supporting healthcare infrastructure. Researchers are continuing to pursue research to target the symptoms, causes, and complications of bronchiectasis, including recurrent infections and chronic inflammation. Other studies are also in train to target mucus clearance or exacerbation issues to better health outcomes and quality of life for the patient.

Bronchiectasis Pipeline Overview:

Supportive government initiatives and growing awareness of bronchiectasis are driving new product development efforts. Several drug candidates are being tested in the stages of preclinical, discovery, and clinical phases through to Phase 3 trials. Drug development companies are focusing on cooperation, mergers, and acquisitions to raise the funds needed for their work. The market is being influenced by licensing and the evaluation of early treatments as well. Healthcare companies are working to obtain official green lights, including U.S. FDA approval, for new therapies for bronchiectasis sufferers.

Here’s a brief insight into some of the upcoming drugs in the pipeline:

• Benralizumab: AstraZeneca

Benralizumab is a humanized IgG1k monoclonal antibody that targets IL-5R alpha chain on eosinophils and basophils. Used for eosinophilic asthma initially, the drug is under Phase III trials for Non-cystic Fibrosis Bronchiectasis.

• S1226: SolAeroMed

The combination of aerosols of CO₂ and nebulized perflubron in S1226 serves to provide rapid relief from airway obstruction. The CO₂ acts as a rapid bronchodilator while perflubron provides prolonged broncho-dilatory effect through surfactant and mucolytic properties.

• Brensocatib: Insmed

Brensocatib inhibits DPP1 reversibly and is administered orally. It reduces the activation of neutrophil serine proteases. By blocking DPP1, it diminishes neutrophil-mediated inflammation and tissue damage in bronchiectasis. The drug acts on the inflammatory pathways that underlie chronic lung destruction.